Key result
Preventive ICD terminates 3 VT episodes in a 21-year-old male with ARVC.
Why the study?
Arrhythmogenic right ventricular cardiomyopathy carries an increased risk for ventricular arrhythmias and sudden cardiac death, particularly in young athletes, emphasizing the importance of early detection and intervention.
Does ICD implantation and medical therapy prevent sudden cardiac death in a young athlete with ARVC?
Case Report (n=1)
No
Does ICD implantation and medical therapy prevent sudden cardiac death in a young athlete with ARVC?
Early multimodal diagnosis and preventive ICD implantation successfully terminated life-threatening ventricular arrhythmias in a young athlete with ARVC.
Answers are grounded in this paper and cite their sources.
Supports ICD consideration in select young ARVC patients; leaves open need for prospective trials before wider adoption.
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a rare inherited cardiomyopathy marked by fibrofatty replacement of right ventricular (RV) myocardium, leading to electrical instability and increased risk for ventricular arrhythmias and sudden cardiac death (SCD). ARVC is typically inherited in an autosomal dominant pattern and often involves mutations in desmosomal proteins such as plakophilin-2 (PKP2). Clinical presentation can vary from asymptomatic to life-threatening arrhythmias, particularly among young athletes. This case emphasizes the importance of early detection and intervention in patients with ARVC. A 21-year-old previously healthy male presented with recurrent exertional syncope. Initial ECG demonstrated sinus rhythm with T-wave inversions in leads V1-V3. Coronary CT angiography and resting echocardiography were normal. However, the stress electrocardiogram revealed frequent premature ventricular complexes (PVCs) with a left bundle branch block morphology. Ambulatory event monitoring detected over 500 monomorphic PVCs in a 24-hour period. Cardiac MRI demonstrated mildly reduced RVEF (39%) with regional dyskinesia, meeting major diagnostic criteria per the 2010 Task Force Criteria for ARVC. Genetic testing confirmed a heterozygous pathogenic mutation (c.1689-1G>C) in the PKP2 gene. The patient was started on beta-blockers and underwent implantation of a single-chamber implantable cardioverter defibrillator (ICD) due to elevated arrhythmic risk. Post-implantation, the ICD successfully terminated three episodes of ventricular tachycardia, highlighting its life-saving role. This case underscores the necessity for a high index of suspicion when evaluating young patients with unexplained syncope or arrhythmias. Diagnosis of ARVC requires integration of clinical, electrocardiographic, imaging, and genetic data. Early diagnosis and prompt management, including activity modification, pharmacologic therapy, and ICD implantation, are critical to mitigating the risk of SCD. Genetic testing and vigilant follow-up remain essential components in the care of ARVC patients.
No takes yet. Share an insight, caveat, or question.
McClellan et al. (2025) conducted a case report in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (n=1). Implantable Cardioverter Defibrillator (ICD) and medical therapy was evaluated on Termination of ventricular tachycardia episodes. A preventive implantable cardioverter-defibrillator successfully terminated three episodes of ventricular tachycardia in a 21-year-old male with arrhythmogenic right ventricular cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: